P/E ratio for Galmed Pharmaceuticals (GLMD)
P/E ratio as of April 2024 (TTM): -0.0598
According to Galmed Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0597907. At the end of 2022 the company had a P/E ratio of -0.0473.
P/E ratio history for Galmed Pharmaceuticals from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.0473 | -48.54% |
| 2021 | -0.0919 | -40.15% |
| 2020 | -0.1536 | -61.34% |
| 2019 | -0.3973 | -50.27% |
| 2018 | -0.7988 | 28.34% |
| 2017 | -0.6224 | 296.35% |
| 2016 | -0.1570 | -70.59% |
| 2015 | -0.5340 | 20.16% |
| 2014 | -0.4444 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Evoke Pharma
EVOK | -0.1896 | 217.14% | 🇺🇸 USA |
 Endo International
ENDPQ | -0.0001 | -99.75% | 🇮🇪 Ireland |
 Aerie Pharmaceuticals AERI | -20.3 | 33,907.46% | 🇺🇸 USA |
 Catalent CTLT | -43.4 | 72,439.88% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.